Photocoagulation for peripheral areas of nonperfusion to prevent the recurrence of diabetic macular edema after intravitreal injection of bevacizumab.

Photocoagulation for peripheral areas of nonperfusion to prevent the recurrence of diabetic macular edema after intravitreal injection of bevacizumab. - Peripheral photocoagulation to prevent the recurrence of diabetic macular edema after bevacizumab-injection .

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007566

Enrollment

Registered

2012-04-15

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

Photocoagulation for peripheral areas of non-perfusion after injection of bevacizumab. Injection of bevacizumab without photocoagulation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patients with macular edema more than 300 micro and hard exdates. Patient who obtained agreement after enough explanation when participating in this study is received.

Exclusion criteria

Exclusion criteria: History of ocular surgery, Ocular diseases except for diabetic macular edema.

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity at 6 months after the injection of bevacizumab.	—

Secondary

Measure	Time frame
Central retinal thickness at 6 months after the injection of bevacizumab.	—

Countries

Japan

Contacts

Public ContactYoshihiro Takamura

Faculty of Medical Sciences, University of Fukui Department of Ophthalmology

ytakamura@hotmail.com0776-61-8403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026